Company profile for Beijing Mabworks Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a Chinese biopharmaceutical company in the clinical stage, focusing on the discovery and development of innovative and differentiated antibody drugs, and committed to becoming a globally integrated biopharmaceutical company. Our mission is to transform scientific breakthroughs in immunology and cancer biology into new antibody therapies, covering the biopharmaceutical market for tumors and autoimmune diseases. This is a...
We are a Chinese biopharmaceutical company in the clinical stage, focusing on the discovery and development of innovative and differentiated antibody drugs, and committed to becoming a globally integrated biopharmaceutical company. Our mission is to transform scientific breakthroughs in immunology and cancer biology into new antibody therapies, covering the biopharmaceutical market for tumors and autoimmune diseases. This is a market that is growing rapidly globally and in China with unmet clinical needs. We will use this opportunity to continue to bring innovative and affordable treatment options to patients in these fields.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
Room 2505, Building T1, Han's Plaza, No. 2 Ronghua South Road, Beijing Economi...
Telephone
Telephone
010-67867467
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/01/09/3006952/0/en/Climb-Bio-Expands-Pipeline-Through-an-Exclusive-License-to-Develop-and-Commercialize-an-Antibody-Targeting-the-APRIL-Pathway-for-IgA-Nephropathy.html

GLOBENEWSWIRE
09 Jan 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty